(Q40413724)

English

Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).

scientific article published on July 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

author name string

Andre J Marozsan

1

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Shawn E Kuhmann

2

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Thomas Morgan

3

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Carolina Herrera

4

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Enid Rivera-Troche

5

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Serena Xu

6

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Bahige M Baroudy

7

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Julie Strizki

8

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

John P Moore

9

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

language of work or name

0 references

publication date

1 July 2005

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

338

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

182-199

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Adaptation to blockade of human immunodeficiency virus type 1 entry imposed by the anti-CCR5 monoclonal antibody 2D7.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

Inhibiting HIV-1 entry with fusion inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

Antigenically distinct conformations of CXCR4.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

The differential sensitivity of human and rhesus macaque CCR5 to small-molecule inhibitors of human immunodeficiency virus type 1 entry is explained by a single amino acid difference and suggests a mechanism of action for these inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

Anti-CXCR4 monoclonal antibodies recognizing overlapping epitopes differ significantly in their ability to inhibit entry of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

Structure of an unliganded simian immunodeficiency virus gp120 core

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

Change in coreceptor use correlates with disease progression in HIV-1--infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

The bicyclam AMD3100 story

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

The amino terminus of human CCR5 is required for its function as a receptor for diverse human and simian immunodeficiency virus envelope glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

G-protein coupled receptors as allosteric machines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

Novel therapies based on mechanisms of HIV-1 cell entry.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

Mechanisms of HIV-1 drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

The current status of, and challenges in, the development of CCR5 inhibitors as therapeutics for HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

Development of a yeast-based recombination cloning/system for the analysis of gene products from diverse human immunodeficiency virus type 1 isolates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

The entry of entry inhibitors: a fusion of science and medicine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

New targets for inhibitors of HIV-1 replication

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

HIV entry inhibitors in clinical development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

Variants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosine-sulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycan

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

Donor- and ligand-dependent differences in C-C chemokine receptor 5 reexpression

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

New therapeutics that modulate chemokine networks

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 2: Discovery of potent, selective, and orally bioavailable compounds

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

Endocytosis and recycling of the HIV coreceptor CCR5

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

Piperazine-based CCR5 antagonists as HIV-1 inhibitors. I: 2(S)-methyl piperazine as a key pharmacophore element

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

Role of low CD4 levels in the influence of human immunodeficiency virus type 1 envelope V1 and V2 regions on entry and spread in macrophages

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and X4 primate immunodeficiency viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

Preferential use of CXCR4 by R5X4 human immunodeficiency virus type 1 isolates for infection of primary lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

Cooperative effects of the human immunodeficiency virus type 1 envelope variable loops V1 and V3 in mediating infectivity for T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

based on heuristic

inferred from DOI database lookup

Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.035

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VIROL.2005.04.035

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40413724&oldid=1507607753"